Current Limitations and Potential Breakthroughs for the Early Diagnosis of Hepatocellular Carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Recently, Gadoxetic acid (Gd-EOB-DTPA; PrimovistⓇ; Bayer Schering Pharma), a tissue-specific contrast material, has been used for clinical MR imaging. This agent is a biphasic hepatobiliary contrast agent because it behaves as both an extracellular and a hepatocyte-specifi c agent as it undergoes both renal and biliary excretion. Up to 50% of the injected dose is taken up into normal hepatocytes due to the presence of the lipophilic ethoxybenzyl group in its chemical structure. As such, dynamic imaging can be performed using this agent for the evaluation of hemodynamic perfusion or status and for hepatobiliary phase imaging (10 to 20 minutes after injection) for the evaluation of functional status. Compared to extracellular contrast materials, Gadoxetic acid-enhanced magnetic resonance imaging (MRI) provides comparable arterial enhancement and prominent venous washout of hepatocellular carcinoma (HCC) during dynamic imaging. Additional hepatobiliary phase images are useful for the detection of small lesions that are not readily visible during dynamic imaging. Current evidence and experience suggest that Gadoxetic acid-enhanced MRI will improve the accuracy of HCC imaging diagnosis by allowing better characterization of hypovascular lesions and better differentiation of small arterial enhancing lesions as well as by providing improved preoperative staging accuracy. Therefore, with the aid of Gadoxetic acid-enhanced MRI, very early HCC will be more commonly diagnosed, with patient treatment occurring in earlier stages of the disease.
Abstract
Recently, Gadoxetic acid (Gd-EOB-DTPA; PrimovistⓇ; Bayer Schering Pharma), a tissue-specific contrast material, has been used for clinical MR imaging. This agent is a biphasic hepatobiliary contrast agent because it behaves as both an extracellular and a hepatocyte-specifi c agent as it undergoes both renal and biliary excretion. Up to 50% of the injected dose is taken up into normal hepatocytes due to the presence of the lipophilic ethoxybenzyl group in its chemical structure. As such, dynamic imaging can be performed using this agent for the evaluation of hemodynamic perfusion or status and for hepatobiliary phase imaging (10 to 20 minutes after injection) for the evaluation of functional status. Compared to extracellular contrast materials, Gadoxetic acid-enhanced magnetic resonance imaging (MRI) provides comparable arterial enhancement and prominent venous washout of hepatocellular carcinoma (HCC) during dynamic imaging. Additional hepatobiliary phase images are useful for the detection of small lesions that are not readily visible during dynamic imaging. Current evidence and experience suggest that Gadoxetic acid-enhanced MRI will improve the accuracy of HCC imaging diagnosis by allowing better characterization of hypovascular lesions and better differentiation of small arterial enhancing lesions as well as by providing improved preoperative staging accuracy. Therefore, with the aid of Gadoxetic acid-enhanced MRI, very early HCC will be more commonly diagnosed, with patient treatment occurring in earlier stages of the disease.
참고문헌 (38)
- Sherman M, "Optimum imaging for small suspected hepatocellular carcinoma", Gut, 59, pp.570~571 (2010)
- International Consensus Group for Hepatocellular Neoplasia, "Pathologic diagnosis of early hepatocellular carcinoma: a report of the International Consensus Group for Hepatocellular neoplasia", Hepatology, 49, pp.658~664 (2009)
- Takayama T, "Early hepatocellular carcinoma as an entity with a high rate of surgical cure", Hepatology, 28, pp.1241~1246 (1998)
- Llovet JM, "Design and endpoints of clinical trials in hepatocellular carcinoma", J Natl Cancer Inst, 100, pp.698~711 (2008)
- Mazzaferro V, "Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis", N Engl J Med, 334, pp.693~699 (1996)
- Singal A, "Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis", Aliment Pharmacol Ther, 30, pp.37~47 (2009)
- Lencioni R, "Surveillance and early diagnosis of hepatocellular carcinoma", Dig Liver Dis, 42(Suppl 3), pp.S223~S227 (2010)
- Forner A, "Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star", Gastroenterology, 137, pp.26~29 (2009)
- Marrero JA, "Alpha-fetoprotein in early hepatocellular carcinoma", Gastroenterology, 138, pp.400~401 (2010)
- Bruix J, "Management of hepatocellular carcinoma", Hepatology, 42, pp.1208~1236 (2005)
- Makuuchi M, "Development of evidencebased clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan", Hepatol Res, 38, pp.37~51 (2008)
- Kudo M, "Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology", Oncology, 72(Suppl 1), pp.2~15 (2007)
- Forner A, "Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma", Hepatology, 47, pp.97~104 (2008)
- Leoni S, "The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria", Am J Gastroenterol, 105, pp.599~609 (2010)
- Sangiovanni A, "The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis", Gut, 59, pp.638~644 (2010)
- Lok AS, "Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma", Gastroenterology, 138, pp.493~502 (2010)
- Santi V, "Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival", J Hepatol, 53, pp.291~297 (2010)
- Federle MP, "Use of radiologic techniques to screen for hepatocellular carcinoma", J Clin Gastroenterol, 35(5 Suppl 2), pp.S92~S100 (2002)
- Yamashita Y, "Small hepatocellular carcinoma in patients with chronic liver damage: prospective comparison of detection with dynamic MR imaging and helical CT of the whole liver", Radiology, 200, pp.79~84 (1996)
- Ringe KI, "Gadoxetate disodiumenhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver", AJR Am J Roentgenol, 195, pp.13~28 (2010)
- Di Martino M, "Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis", Radiology, 256, pp.806~816 (2010)
- Cruite I, "Gadoxetate disodiumenhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver", AJR Am J Roentgenol, 195, pp.29~41 (2010)
- 정용은, "Added Value of Gadoxetic Acid-enhanced Hepatobiliary Phase MR Imaging in the Diagnosis of Hepatocellular Carcinoma", RADIOLOGY, 255, pp.459~466, RADIOLOGICAL SOC NORTH AMERICA
- Hamm B, "Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging", Radiology, 195, pp.785~792 (1995)
- Motosugi U, "Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging", Radiology, 256, pp.151~158 (2010)
- Sun HY, "Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging", Invest Radiol, 45, pp.96~103 (2010)
- O’Malley ME, "Outcome of small (10-20 mm) arterial phase-enhancing nodules seen on triphasic liver CT in patients with cirrhosis or chronic liver disease", Am J Gastroenterol, 100, pp.1523~1528 (2005)
- Jeong YY, "Small (<20 mm) enhancing hepatic nodules seen on arterial phase MR imaging of the cirrhotic liver: clinical implications", AJR Am J Roentgenol, 178, pp.1327~1334 (2002)
- Holland AE, "Importance of small (< or=20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver", Radiology, 237, pp.938~944 (2005)
- Shimizu A, "Cirrhosis or chronic hepatitis: evaluation of small (<or=2-cm) earlyenhancing hepatic lesions with serial contrast-enhanced dynamic MR imaging", Radiology, 226, pp.550~555 (2003)
- Kim YK, "Clinical implication of small (<20 mm) enhancing hepatic nodules observed only during three-dimensional gadobenate dimeglumine-enhanced hepatic arterial-phase MRI of the hepatitis B virus-induced mild cirrhosis", Clin Imaging, 32, pp.453~459 (2008)
- Park MJ, "Outcomes of follow-up CT for small (5-10-mm) arterially enhancing nodules in the liver and risk factors for developing hepatocellular carcinoma in a surveillance population", EUROPEAN RADIOLOGY, 20(10), pp.2397~2404, SPRINGER
- Marrero JA, "Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass", Liver Transpl, 11, pp.281~289 (2005)
- van den Bos IC, "MR imaging of hepatocellular carcinoma: relationship between lesion size and imaging findings, including signal intensity and dynamic enhancement patterns", J Magn Reson Imaging, 26, pp.1548~1555 (2007)
- Hayashida M, "Small hepatocellular carcinomas in cirrhosis: differences in contrast enhancement effects between helical CT and MR imaging during multiphasic dynamic imaging", Magn Reson Imaging, 26, pp.65~71 (2008)
- Khan AS, "Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver", J Magn Reson Imaging, 32, pp.360~366 (2010)
- Sakamoto M, "Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multiinstitutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection", Jpn J Clin Oncol, 28, pp.604~608 (1998)
- Kalinski T, "Hepatocellular carcinoma: pathology and liver biopsy", Dig Dis, 27, pp.102~108 (2009)